MAX Lab

Laboratory Investigation Report

Patient Name	: Mr. Mustafa Abdullah	Centre	:
Age/Gender	: 47 Y 0 M 0 D /M	OP/IP No/UHID	: //
MaxID/Lab ID	: SKMS.645554/3928102300229	Collection Date/Time	: 25/Oct/2023 04:15PM
Ref Doctor	: SELF	Reporting Date/Time	: 03/Nov/2023 10:03AM

SIN No:B2B4339691

Molecular Diagnostics

Test Name	Result	Unit	Bio Ref Interval

BCR-ABL Kinase Domain(KD) Mutations IRMA, EDTA

PCR, Sequencing

BCR-ABL Kinase Domain(KD) Mutations IRMA	Not Detected		

	THERAPY	CONTRAINDICATED MUTATIONS
BCR::ABL1 kinase domain contraindicated mutations based on NCCN GUIDELINES VERSION 1.2023	Asciminib	A337T or P465S
	Bosutinib	T315I, V299L, G250E, or F317L
	Dasatinib	T315I/A, F317L/V/I/C, or V299L
	Nilotinib	T315I, Y253H, E255K/V, or F359V/C/I
	Ponatinib, Omacetaxine, allogeneic HCT (CML-6), or clinical trial	None

NOTE :

1. This lab developed assay detects all point mutations in the BCR-ABL1 kinase domain spanning from amino acids 237 to 478. This assay does not detect variants in other parts of this gene.
2. Not Detected/Indeterminate result might be due to the presence of mutations below the detection limit of the assay i.e 20% VAF for Sanger sequencing.
3. Presence of PCR inhibitors in the sample may prevent DNA amplification.
4. All results should be interpreted in context of clinical findings.
5. Genetic counselling is recommended.

COMMENTS :

BCR-ABL1 kinase domain mutational analysis is helpful in the selection of subsequent TKI therapy for patients with inadequate initial response to first-line or second-line TKI therapy. Point mutations in the BCR-ABL1 kinase domain are a frequent mechanism of secondary resistance to TKI therapy and are associated with poor prognosis and higher risk of disease progression. Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutively active tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Patients with disease resistant to primary treatment with imatinib should be treated with bosutinib, dasatinib, or nilotinib in the second-line setting, taking into account BCR::ABL1 kinase domain mutation status.

Kindly correlate with clinical findings

***** End Of Report *****

Dr. Nitin Dayal, M.D.
Principal Consultant & Head,
Haematopathology

Dr Atul Thatai, Ph.D
Director
Molecular and Cyto Genomics

Test Performed at :910 - Max Hospital - Saket M S S H, Press Enclave Road, Mandir Marg, Saket, New Delhi, Delhi 110017
Booking Centre :4648 - Dr. Rohit Kapoor, House No. -100A/7, One Shop on Ground Floor, 8750033675
The authenticity of the report can be verified by scanning the Q R Code on top of the page

Max Lab Limited (A Wholly Owned Subsidiary of Max Healthcare Institute Ltd.)
Max Super Speciality Hospital, Saket (West Block), 1, Press Enclave Road, Saket, New Delhi - 110 017, Phone: +91-11-6611 5050
(CIN No.: U85100DL2021PLC381826)
Helpline No. 7982 100 200 www.maxlab.co.in feedback@maxlab.co.in

MC-2714